Medical weight management has transformed the treatment of obesity in recent years. Medications such as GLP-1 receptor agonists, including semaglutide and tirzepatide, have helped many patients achieve significant and sustained weight loss where previous approaches had failed. For some individuals, these treatments reduce appetite, improve control over eating behaviours, and support long-term weight management in a way that lifestyle measures alone often cannot.
However, not everybody responds to treatment in the same way. While some patients experience substantial weight loss, others lose only a modest amount of weight or struggle to maintain their progress despite adherence to treatment and lifestyle changes. Some patients also experience side effects that limit their ability to continue medication. This variability can feel frustrating and discouraging, particularly for individuals who are making considerable efforts to improve their health.
The reason for this lies in the complex biology of obesity. Weight regulation is not determined simply by willpower or calorie intake. Obesity is now recognised as a chronic and multifactorial disease influenced by hormones, genetics, metabolism, behaviour, environment and neurobiology. The body has sophisticated systems designed to maintain energy balance and protect against weight loss, many of which can work against individuals attempting to lose weight.
When a person loses weight, the body often responds by activating compensatory mechanisms intended to restore previous weight levels. Hunger signals may increase, satiety may decrease, and metabolic rate may slow in an attempt to conserve energy. This biological adaptation explains why many people experience persistent hunger and fatigue during weight loss and why maintaining weight loss can be so challenging.
The role of hormones in appetite and weight regulation
Hormones play a central role in this process. Two hormones that are particularly important are leptin and ghrelin. Leptin is involved in long-term regulation of energy balance and helps signal fullness to the brain. In many people living with obesity, the body develops leptin resistance, meaning the brain no longer responds effectively to these satiety signals. Ghrelin, often referred to as the “hunger hormone,” stimulates appetite and increases food-seeking behaviour. Research suggests that individuals with higher baseline ghrelin levels and greater suppression of ghrelin after eating may respond more favourably to GLP-1 analogue therapy. This may partly explain why some patients experience dramatic appetite reduction on treatment while others notice more limited effects.
GLP-1 receptor agonists work by mimicking naturally occurring hormones involved in appetite regulation. They slow gastric emptying, increase feelings of fullness, reduce appetite, and improve blood glucose control. Although these medications are highly effective for many patients, response rates remain highly variable. Differences in hormonal regulation, metabolic efficiency, insulin resistance, genetics, gut microbiome composition, sleep quality, stress levels, physical activity, and concurrent medications can all influence outcomes.
Genetics, metabolism and biological adaptation
Genetics also appear to play an increasingly important role in determining response to weight management interventions. Research has shown that individuals differ significantly in how their bodies regulate appetite, store fat, and respond to calorie restriction. Variations in resting metabolic rate, energy expenditure, thermogenic response to food, and non-exercise activity thermogenesis may all contribute to differences in weight loss capacity. Some individuals appear biologically predisposed to stronger metabolic adaptation during weight loss, making ongoing progress substantially more difficult despite adherence to treatment.
Another important factor is early treatment response. Studies consistently show that individuals who achieve greater initial weight loss are more likely to experience long-term success. Patients who respond well early in treatment often report stronger appetite suppression and improved adherence to lifestyle changes. However, a slower response does not necessarily mean treatment has failed. Some patients require longer treatment duration, dose optimisation, additional behavioural support, or alternative therapeutic approaches before meaningful progress is achieved.
Why side effects can limit weight loss progress
Side effects can also significantly influence treatment outcomes and may limit the ability to optimise therapy. Although GLP-1 receptor agonists are generally well tolerated and highly effective for many patients, gastrointestinal side effects are relatively common, particularly during dose escalation. Symptoms such as nausea, vomiting, constipation, diarrhoea, bloating, abdominal discomfort, reflux symptoms, and fatigue can vary considerably in severity between individuals. For some patients, these symptoms are mild and temporary, while for others they can become sufficiently burdensome to interfere with daily functioning, nutritional intake, social activities, work, or overall quality of life.
One of the key challenges in medical weight management is that the most effective therapeutic doses are not always the most tolerable doses. GLP-1 receptor agonists typically escalate gradually over time in order to improve tolerability and achieve greater appetite suppression and weight loss. However, some patients are unable to tolerate dose escalation beyond lower maintenance doses because side effects become limiting. In these situations, patients may remain on what is effectively a suboptimal dose from a weight loss perspective.
This is an important clinical consideration because weight loss outcomes are often dose-dependent. Patients who cannot progress to higher therapeutic doses may experience less appetite suppression, less improvement in food noise, and reduced overall weight loss compared with those able to tolerate full treatment escalation. This does not necessarily indicate treatment failure, but rather reflects the balance clinicians must achieve between efficacy and safety.
In some cases, attempts to escalate treatment too quickly can worsen symptoms and negatively affect adherence, leading patients to discontinue therapy altogether. Careful pacing of dose increases, temporary dose pauses, dietary modification, hydration advice, and supportive management of gastrointestinal symptoms can often improve tolerability. Nevertheless, there remains a subset of patients for whom side effects continue despite these measures. There is also increasing recognition that individual variation in gastric emptying, gut-brain signalling, visceral sensitivity, and neurohormonal responses may partly explain why some patients tolerate these medications exceptionally well while others struggle with persistent adverse effects. Concurrent medical conditions, anxiety surrounding symptoms, pre-existing gastrointestinal disorders, and other medications may further compound tolerability issues.
For this reason, successful obesity treatment is not simply about prescribing the highest available dose. Effective medical weight management requires an individualised approach that balances clinical benefit with quality of life, sustainability, and patient preference. In some patients, maintaining a lower but tolerable dose that provides modest appetite control and weight stability may ultimately be more beneficial than pursuing aggressive dose escalation that cannot be sustained long term.
Lifestyle factors that influence weight loss
Another often-overlooked factor in successful weight loss is sleep quality. Poor sleep and chronic stress can significantly impair weight loss efforts, even in patients who are following appropriate dietary and exercise plans. Sleep deprivation disrupts the body’s hormonal regulation of appetite and metabolism, leading to increased hunger, reduced satiety, and a greater tendency to crave highly processed, calorie-dense foods. Studies have shown that individuals sleeping fewer than 6–7 hours per night are at increased risk of obesity, insulin resistance and poorer long-term weight management outcomes.
Sleep restriction has also been associated with increased ghrelin levels, reduced leptin levels, increased caloric intake, and reduced fat loss during calorie restriction. In one study, individuals with inadequate sleep lost significantly less body fat despite following the same calorie deficit as well-rested participants.
Chronic stress further compounds this problem through elevated cortisol levels. Cortisol is the body’s primary stress hormone and, when persistently elevated, can promote fat storage, particularly around the abdomen, increase appetite, impair glucose metabolism, and drive cravings for sugar and high-fat foods. High cortisol levels may also contribute to fatigue, reduced motivation for physical activity, and poorer recovery from exercise.
Good quality sleep is therefore not simply restorative, it is a fundamental component of metabolic health and effective weight management. Prioritising 7–9 hours of consistent, high-quality sleep alongside stress reduction strategies can significantly improve appetite regulation, energy balance, and long-term weight loss success.
Personalised treatment Is essential in obesity management
Perhaps the most important point is that obesity is not the same disease in every patient. Two individuals with identical body mass indices may have completely different hormonal profiles, appetite regulation systems, metabolic responses, psychological drivers of eating behaviour, and genetic predispositions. As a result, a treatment that works exceptionally well for one person may provide only modest benefit for another.
For this reason, modern obesity management increasingly focuses on personalised care. Effective treatment often requires a combination of nutritional support, behavioural intervention, physical activity optimisation, psychological support, medication management and long-term follow-up. For some patients, bariatric surgery may also be appropriate.
GLP-1 receptor agonists have undoubtedly revolutionised obesity treatment and have provided life-changing results for many patients. However, variability in response is normal and reflects the complex biological systems involved in human weight regulation. A limited response to treatment should not be viewed as a failure of motivation or willpower. Understanding the biological complexity of obesity helps reduce stigma and supports a more compassionate, evidence-based approach to long-term weight management.
